Adherium’s Post

ClavystBio CEO Khoo Shih sat down with Citeline Commercial Scrip’s Mandy Jackson to discuss the growing traction in the biotech market. Financing is showing signs of improvement, driven by increased M&A activity from big pharma acquiring smaller firms at attractive valuations. IPOs for clinical-stage companies are also on the rise. Khoo Shih highlighted that while financing prospects are improving, success hinges on companies with a well-articulated story and clear milestones: Key takeaways: • Clarity in Milestones: This is a pivotal time for biotechs to sharpen strategies and communicate their milestones. Investors are looking for companies that can articulate a clear path to value-creating clinical milestones. • Platform Potential: While platforms are valued, the real focus is on the progression of drug candidates. • Strong Insider Commitment: Demonstrating robust internal support is crucial. Read the full article here (for subscribers only): https://lnkd.in/g7DZjZwz

France: Case Study - Amolyt Pharma, a portfolio company of Sofinnova Partners sold to AstraZeneca for $1.05bn. Amolyt Pharma represents a major European VC success story – a French company created and incubated by a pioneering entrepreneur, backed by top European investors, including Sofinnova Partners, who led the company’s €130M series C in 2023, with participation from Intermediate Capital Group (ICG) Tekla Capital Investment LLC, CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital. READ the Invest Europe case study here https://lnkd.in/emQzXubz READ the Investors in Healthcare article here https://lnkd.in/ex8GPi53 #lifesciences #venturecapital #healthcare Antoine Papiernik Nicholas Moore Julian Hudson

The right to health is a basic human right 🏥 On #WorldHealthDay, Amolyt Pharma, with backing from Sofinnova Partners, offers hope to patients worldwide suffering from rare endocrine and related diseases. 💫 €212m raised from VCs 💫 Expansion to 50 employees 💫 $1.05bn acquisition agreement with AstraZeneca With support from investors: Intermediate Capital Group (ICG), Tekla Capital Management, CTI Life Sciences Fund, Andera Partners, Novo Ventures, Kurma Partners, EQT Life Sciences, @Innobio 2 (Bpifrance Investissement), Sectoral Asset Management, Pontifax Venture Capital, OrbiMed, Mass General Brigham Ventures, ATEM, Crédit Agricole Création and Relyens Innovation Santé / Turenne Groupe. Read the full story, and take a look at how investment supports Europe’s most innovative healthcare and life sciences businesses ➡️ https://lnkd.in/emQzXubz #PrivateEquity #VentureCapital #SuccessStories #BuildingBetterBusinesses #pharma #healthcare

HQH: Disappointing Track Record Summary The abrdn Healthcare Investors (HQH) fund has a 36-year track record of underperforming peers that does not create confidence for future results. HQH focuses on mid and large-cap biotech and pharmaceutical companies in late-stage clinical trials i.e. FDA approval catalysts. Capital gains distribution requires reinvestment to achieve compounding returns. Conclusion I rate the HQH a sell. While the current portfolio does not concern nor excite me, the manager's consistently poor track record is a no-go. Unlike passive funds where one identifies a strict investment process and can agree or disagree with its validity, actively managed funds require confidence in stock selection, research, etc. This fund was acquired by abrdn last year but is maintaining the same team it had as Teka Capital, which most likely means the same strategy and research will drive decisions that have underperformed peers. https://lnkd.in/e2hKKQPC

#Partnerships with external investors like Tesi are crucial for BC Platforms' growth and internationalization. 🚀 #data #drugdevelopment #healthcare #precisionmedicine #healthtech #healthtechinnovation

"Amidst challenges in the biotech industry, patience is key. Despite a tough year marked by lower valuations and layoffs, we are witnessing green shoots in the sector, including M&A activities and select IPO transactions. Additionally, there are favourable regulatory and clinical outlooks for innovative precision medicines. It is important to remember that successful biotech investments often demand long-term commitment, as breakthrough scientific innovations take time to materialise."   Yesterday, at the 3rd BioCentury-BayHelix East-West Biopharma Summit 2024 🧪 in Singapore, Jolene Ooi advised and shared perspectives on the biotech and #healthtech funding landscape in this region on the topic of ‘Capital Markets: The Buy Side’. Many thanks to BioCentury Inc. for the invitation to contribute to this panel discussion along with Wai Chiew CHIK, Curtis S. Chin, George Lin, Matthew Sheroff, and Yue (Shelby) Zhang. #EDBI #healthcareinnovation #healthcare

LianBio announces its closure, delisting from Nasdaq, and plans to return $528 million to shareholders via a special cash dividend of $4.80 per share. This decision follows asset sales to Bristol Myers Squibb and Johnson & Johnson and a strategic review aiming to maximize shareholder returns in a challenging biotech market. Key Points: 🔷 Closure and workforce reduction to focus on maximizing shareholder returns. 🔷 Special cash dividend and profits from asset divestments to be distributed. 🔷 Reflects strategic adaptability in response to the biotech industry's challenges. #Biotech #LianBio #ShareholderValue

📣 We are pleased to announce that Cuprina Holdings, a Singapore-based biomedical and biotechnology company, is preparing for its IPO and inviting investors to participate. 📌 Access to the IPO is available through NVB for a seamless investment experience. The company specializes in the development and commercialization of innovative products for chronic wound care, as well as cosmeceuticals for the healthcare and beauty sectors. Deal Terms: ◽ Security type: Common Shares ◾ Offering type: IPO ◽Expected IPO date: Late August 2024 ◾Listing exchange: NASDAQ ◽Ticker symbol: CUPR ◾Offering size: $15 million ◽Expected price per share: $4 ◾Minimum investment: $25,000 ◽Brokerage fee: 5% ◾Application start date: August 12, 2024 📈 Cuprina Holdings is poised to make a significant impact in the global healthcare market. Stay tuned for more updates. #IPO #Biotechnology #BiomedicalResearch #CuprinaHoldings #Healthcare #Innovation #NASDAQ

Thoughts on this? >> Brise raises $20M; Taro shareholder criticizes Sun Pharma deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #biotech #productmarketing

Thoughts on this? >> Brise raises $20M; Taro shareholder criticizes Sun Pharma deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #biotech #pharmaceutical